Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs PRINCIPEN '125'
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Ampicillin is a penicillin beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Treatment of infections caused by susceptible gram-positive and gram-negative bacteria, including respiratory tract infections, otitis media, sinusitis, urinary tract infections, meningitis, septicemia, and gastroenteritis.,Off-label: Prophylaxis for bacterial endocarditis, treatment of listeriosis, and Lyme disease.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg to 1 g every 6 hours for severe infections.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life: 0.7-1.4 hours in adults with normal renal function. Prolonged in renal impairment (up to 7-10 hours in anuria).
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Ampicillin is metabolized by hydrolysis to penicilloic acid, primarily in the liver. It also undergoes renal tubular secretion.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal: approximately 60-80% of the dose excreted unchanged in urine via tubular secretion and glomerular filtration. Biliary/fecal: minimal, <10%.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Approximately 20-30% bound to serum proteins, primarily albumin.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
0.3-0.4 L/kg, approximating extracellular fluid volume. Higher in neonates and critically ill patients due to increased extracellular water.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral: 30-50% due to acid lability and incomplete absorption. IM: nearly 100%.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-16 hours.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
No dose adjustment required.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Infants and children: 12.5-25 mg/kg orally every 6 hours. For severe infections: up to 50 mg/kg/day in divided doses every 6 hours.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Dose based on renal function; use lower end of dosing interval due to age-related decline in renal function.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
No FDA black box warning.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have occurred.,Clostridium difficile-associated diarrhea (CDAD) reported with nearly all antibacterial agents.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Dosage adjustment required in renal impairment.,Safety in pregnancy: Category B; use only if clearly needed.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics.,Infections caused by beta-lactamase-producing organisms (ampicillin is susceptible to beta-lactamase degradation).
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Take on an empty stomach. Food, especially acidic beverages or fruit juices, may reduce absorption. Avoid alcohol concurrently. No specific dietary restrictions.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Inadequate human data in first trimester; risk cannot be excluded. Penicillins are generally considered low risk throughout pregnancy.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Excreted into breast milk in low amounts (M/P ratio approximately 0.5). Considered compatible with breastfeeding; monitor infant for rash, diarrhea, or candidiasis.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No significant pharmacokinetic changes requiring dose adjustment. Increased renal clearance and expanded plasma volume may lower serum concentrations, but standard dosing remains effective. Adjust only if renal function significantly declines.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Principen '125' (ampicillin) is a broad-spectrum penicillin. Note that it is inactivated by beta-lactamases; use with a beta-lactamase inhibitor for resistant organisms. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Monitor for hypersensitivity reactions, especially rash; ampicillin rash is common in patients with Epstein-Barr virus or concurrent allopurinol use. Adjust dose in renal impairment (Cr Cl <30 m L/min).
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Complete the entire prescribed course even if you feel better.,Inform your doctor if you develop a rash, diarrhea, or signs of an allergic reaction.,Avoid alcohol while taking ampicillin to reduce side effects.,Use effective contraception if applicable; ampicillin may reduce oral contraceptive efficacy.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs PRINCIPEN '125', answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. PRINCIPEN '125' is a Aminopenicillin Antibiotic that works by Ampicillin is a penicillin beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and PRINCIPEN '125' depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of PRINCIPEN '125' is: 250-500 mg orally every 6 hours for mild to moderate infections; 500 mg to 1 g every 6 hours for severe infections.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and PRINCIPEN '125' in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. PRINCIPEN '125' is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Inadequate human data in first trimester; risk cannot be excluded. Penicillins are generally considered l. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.